{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-23-000007","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.539580+00:00","generated_at":"2026-06-17T18:59:44.836507+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics reports Q4 2022 net loss $11.9M; cash runway extended through Q4 2024","bullets":["Net loss $11.9M for Q4 2022, compared to $17.9M in Q4 2021; full year net loss $53.8M (2021: $50.0M).","Cash and equivalents $129.3M at Dec 31, 2022; company drew down full $40M term loan, extending runway through at least Q4 2024.","Collaboration revenue $7.3M (Q4 2022) from Jazz licensing agreement; zero in prior year period.","Phase 1/1b WTX-124 (IL-2) dose-escalation ongoing; interim data expected in Q4 2023.","First patient dosed in Phase 1 WTX-330 (IL-12) trial in Feb 2023; WTX-712 (IL-21) nominated for preclinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-23-000007","json":"https://secwatch.observer/filing/0001785530-23-000007.json","markdown":"https://secwatch.observer/filing/0001785530-23-000007.md","text":"https://secwatch.observer/filing/0001785530-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/0001785530-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/howl-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:59:44.836507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e109ed23016ac3a77e499eae1abfedac2bcb120","claim":"Werewolf Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (raised).","evidence_excerpt":"On March 23, 2023, Werewolf Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing financial results for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000007/0001785530-23-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}